Top 3 Most Read DE&I Articles of 2023
Authors in this area focused on increasing diversity in clinical trials through patient-first payment options and trial design.
Below are the most read diversity, equity, and inclusion (DE&I) articles featured on Applied Clinical Trials in 2023.
1. Increasing Clinical Trial Diversity Through Patient-First Payment Options
Patient-first trial design, based around the tenets of adaptability and personalization, has emerged as a key solution to increase diversity and improve trial outcomes for all. There is an increasing focus on the need to flex trial designs to meet the needs of participants, whether they are logistical, financial, or educational.
However, uptake of new technologies that offer patient optionality is far from universal, in part due to the industry’s desire to stay in its comfort zone. This hesitation is particularly apparent in clinical trial payments.
Read the full article here.
2. 12 Questions We Need to Answer to Achieve Diversity in Clinical Research
DE&I has, deservedly, become a hot topic in clinical research. Numerous organizations are developing methodologies, products and programs. If “let a thousand flowers bloom” is the best way to achieve diversity, we are certainly on track. However, we should be able to minimize duplicative efforts and accelerate learning through collaboration. The best place to start this collaboration is to develop consensus answers to the following 12 fundamental questions.
Read the full article here.
3. The Impact of Trial Design on Interest by Race and Ethnicity
The life sciences industry is collectively recommitted to better addressing challenges to diversity and inclusion in clinical trials, especially among traditionally underserved populations. What we know is that there is no singular formula to effectively resolve this longstanding issue. As such, clinical trial sponsors, their contract research organization (CRO) partners, and other industry stakeholders are recognizing the importance of approaching each trial program with a deliberate focus on diversity goals during trial design and planning activities.
Read the full article here.
Walgreens, Boehringer Ingelheim Agree to Collaboration on Enhancing Clinical Trial Diversity
May 2nd 2024Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, weight issues, and type 2 diabetes, mainly in historically underrepresented groups.
Enhancing Diversity Through Trial Design
April 3rd 2024In part 2 of this video interview with ACT editor Andy Studna, Tirisham Gyang, MD, assistant professor of neurology at The Ohio State University discusses how industry can effectively enroll patients from underrepresented populations into their trials.
